TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31393809

Group type: EXPERIMENTAL
Intervention: Decision Aid
Number of subjects: 29
Study: 29122523

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg of a 20% SCIg solution (IgPro20) weekly
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg of a 20% SCIg solution (IgPro20) weekly
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (2% human albumin solution)
Number of subjects: 172

Group type: COMPARATOR
Intervention: 0.2 g/kg SCIg vs Placebo
Number of subjects: 172

Group type: COMPARATOR
Intervention: 0.4 g/kg SCIg vs Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg SCIg vs 0.2 g/kg SCIg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Causally related adverse events
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 172
Study: 27633186

Group type: EXPERIMENTAL
Intervention: Semaglutide (0.5 mg or 1.0 mg)
Number of subjects: 3297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 3297
Study: 25523957

Group type: EXPERIMENTAL
Intervention: Cool Mint ListerineR (MWa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periobacter R (MWb)
Number of subjects: 0
Study: 23153360

Group type: EXPERIMENTAL
Intervention: Insecticide-treated school uniforms (impregnated with permethrin)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (standard school uniforms without insecticide treatment)
Number of subjects: 2000
Study: 21142442

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy including lopinavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of interferon in plasma of AIDS patients
Number of subjects: 0
Study: 17484706

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) in the form of commercially available yoghurt, 100 g daily for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard pasteurised yoghurt (control group)
Number of subjects: 27
Study: 16424955

Group type: EXPERIMENTAL
Intervention: Conventional electrosurgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Computer-controlled bipolar electrosurgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ultrasonic shears (Harmonic Scalpel)
Number of subjects: 38

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 38
Study: 14764410

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg per os daily for 120 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (for 120 days, followed by 60 days of only placebo)
Number of subjects: 200
Study: 10533328

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Phenytoin sodium (Group B)
Number of subjects: 50
Study: 8615544

Group type: EXPERIMENTAL
Intervention: High-pressure sodium discharge lamp with improved coefficiency of transmitting the colours (HPSM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Filament lamps (GL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard sodium discharge lamp (HPS)
Number of subjects: 63
Study: 2344897

Group type: COMPARATOR
Intervention: Quinidine (1200 mg/die)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lidoflazine (240 mg/die)
Number of subjects: 115
Study: 6108724

Group type: EXPERIMENTAL
Intervention: Refined timothy pollen extract (R)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Whole timothy pollen extract (W)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 31986897

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 74

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 74
Study: 31488353

Group type: EXPERIMENTAL
Intervention: Delayed coronary intervention (22.7 hours)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Immediate coronary intervention (0.4 hours)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups (Delayed and Immediate)
Number of subjects: 142
Study: 29231159

Group type: EXPERIMENTAL
Intervention: Intra-articular lumbar facet-joint injections with steroids
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined physical and psychological (CPP) programme
Number of subjects: 9
Study: 25764523

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (8 J/cm², 1064 nm, 60 sec, 0.5 W)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no laser treatment)
Number of subjects: 10
Study: 24073995

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo/Sitagliptin
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 451
Study: 22996721

Group type: EXPERIMENTAL
Intervention: Correct prior knowledge of walking terrain
Number of subjects: 9

Group type: COMPARATOR
Intervention: Incorrect prior knowledge of walking terrain
Number of subjects: 9
Study: 19541948

Group type: EXPERIMENTAL
Intervention: Exercise counseling (10 weeks, individually delivered)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health education contact control (10 weeks)
Number of subjects: 60
Study: 17334593

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40
Study: 15125520

Group type: EXPERIMENTAL
Intervention: Daily topical application of 1/3 diluted camphor oil with glycerol and 500 mg metronidazole orally for fifteen days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (12 females free from other dermatological lesions)
Number of subjects: 27
Study: 11779901

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg every 4 hours for 24 hours
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo every 4 hours for 24 hours
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 39
Study: 9640568

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine 1 hour before and immediately after surgery (group C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine 1 hour before surgery (group B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo treatment (group A)
Number of subjects: 51
Study: 8074628

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4 mg.kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2561141

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine twice a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril once a day
Number of subjects: 27
Study: 781835

Group type: EXPERIMENTAL
Intervention: Bromhexine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Guaiphenesine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29635951

Group type: EXPERIMENTAL
Intervention: Bilateral internal iliac artery (IIA) ligation followed by caesarean hysterectomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (caesarean hysterectomy only)
Number of subjects: 57
Study: 28004215

Group type: EXPERIMENTAL
Intervention: Aripiprazole (1-15 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 25970252

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) administered 1 hour before each of 5 exposure and response prevention tasks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo administered 1 hour before each of 5 exposure and response prevention tasks
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 23625077

Group type: EXPERIMENTAL
Intervention: Cyclical movements at three prescribed frequencies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quasistatic conditions
Number of subjects: 0
Study: 21091697

Group type: EXPERIMENTAL
Intervention: Iron supplementation for 16 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no iron substitution)
Number of subjects: 116
Study: 19125674

Group type: EXPERIMENTAL
Intervention: Treatment of Helicobacter pylori infection
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: H. pylori-negative children
Number of subjects: 219
Study: 17454420

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15342174

Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 428

Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Rate control and Rhythm control
Number of subjects: 428
Study: 11510809

Group type: EXPERIMENTAL
Intervention: FI,O2=0.3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FI,O2=0.5
Number of subjects: 10
Study: 9579296

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 18800457

Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2694856

Group type: EXPERIMENTAL
Intervention: Prophylactic selective flora suppression regimen consisting of polymyxin E, tobramycin and amphotericin B
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 409592

Group type: EXPERIMENTAL
Intervention: Dynamically oriented psychotherapy for over one year
Number of subjects: 20

Group type: COMPARATOR
Intervention: Therapist randomly assigned (Clinic staff member or senior resident in psychiatry)
Number of subjects: 20
Study: 31405721

Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial injury (n = 124)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (n = 115)
Number of subjects: 239
Study: 28453838

Group type: EXPERIMENTAL
Intervention: Multivalent GI.1 and GII.4c norovirus VLP vaccine candidate adjuvanted with alum and MPL
Number of subjects: 0
Study: 26515660

Group type: EXPERIMENTAL
Intervention: Continue donepezil without memantine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Discontinue donepezil without memantine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Discontinue donepezil and start memantine
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Continue donepezil and start memantine
Number of subjects: 295

Group type: COMPARATOR
Intervention: Combined donepezil discontinuation groups
Number of subjects: 295

Group type: COMPARATOR
Intervention: Combined donepezil continuation groups
Number of subjects: 295

Group type: COMPARATOR
Intervention: Starting memantine
Number of subjects: 295
Study: 22834862

Group type: EXPERIMENTAL
Intervention: Robotic endoscope holder
Number of subjects: 20
Study: 21076285

Group type: EXPERIMENTAL
Intervention: Socioemotional stress condition
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control condition (without socioemotional stress)
Number of subjects: 19
Study: 18663402

Group type: EXPERIMENTAL
Intervention: Higher doses of ibandronate (ACE doses > or = 10.8 mg: 150 mg once monthly, 3 mg i.v. quarterly, 2 mg i.v. every 2 months)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lower doses of ibandronate (ACE doses of 5.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ACE doses of 7.2‐12 mg
Number of subjects: 8
Study: 16708044

Group type: EXPERIMENTAL
Intervention: Home-based nursing intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121

Group type: COMPARATOR
Intervention: Posttest-only comparison group
Number of subjects: 121
Study: 15028347

Group type: EXPERIMENTAL
Intervention: Ablative procedures (coronary atherectomy, laser angioplasty, cutting balloon atherotomy)
Number of subjects: 9222
Study: 15028852

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 90
Study: 10679645

Group type: EXPERIMENTAL
Intervention: Lanreotide 30 mg intramuscularly every 10 days for 1 month
Number of subjects: 33

Group type: COMPARATOR
Intervention: Octreotide 200 microg subcutaneously twice or thrice daily for 1 month
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lanreotide and octreotide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 33

Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 33
Study: 9357942

Group type: EXPERIMENTAL
Intervention: Brainstem, middle latency, and cortical auditory evoked responses (BMC‐AERs)
Number of subjects: 81
Study: 8404404

Group type: EXPERIMENTAL
Intervention: Olsalazine (2 g daily)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 3090849

Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 123

Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 123
Study: 2688972

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 30651059

Group type: EXPERIMENTAL
Intervention: Telephone call and text message intervention provided by trained nurses.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 120
Study: 28493741

Group type: EXPERIMENTAL
Intervention: 0.45g/kg alcohol dose in activational condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.65g/kg alcohol dose in activational condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo in activational condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.45g/kg alcohol dose in inhibitory condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.65g/kg alcohol dose in inhibitory condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo in inhibitory condition
Number of subjects: 40
Study: 29400027

Group type: EXPERIMENTAL
Intervention: Soft-CliP® piston
Number of subjects: 20

Group type: COMPARATOR
Intervention: Causse® Teflon prosthesis
Number of subjects: 20
Study: 23283838

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21550760

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) reconstruction
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) single-bundle reconstruction
Number of subjects: 55

Group type: COMPARATOR
Intervention: Posterolateral (PL) single-bundle reconstruction
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lysholm score
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Tegner score
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: KT-1000 arthrometer
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Manual pivot-shift test
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Muscle strength (knee extensor and flexor isokinetic peak torques at 60°/s)
Number of subjects: 55
Study: 19633577

Group type: EXPERIMENTAL
Intervention: Balsalazide 6.75 g/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Balsalazide 2.25 g/day
Number of subjects: 68
Study: 17597253

Group type: EXPERIMENTAL
Intervention: Eating a piece of chocolate
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Eating palatable chocolate
Number of subjects: 161

Group type: COMPARATOR
Intervention: Drinking water
Number of subjects: 161

Group type: COMPARATOR
Intervention: Eating unpalatable chocolate
Number of subjects: 161
Study: 15531051

Group type: COMPARATOR
Intervention: Grip-measuring device with different shaped end-objects; tracking tasks including ramp-tracking and sinus-tracking.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ramp-tracking task
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sinus-tracking task
Number of subjects: 29
Study: 11421842

Group type: COMPARATOR
Intervention: Bupivacaine 1 ml kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 ml kg(‐1) + Tramadol 1.5 mg kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg kg(‐1)
Number of subjects: 60
Study: 9735661

Group type: EXPERIMENTAL
Intervention: Atopic subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-atopic subjects
Number of subjects: 20
Study: 7983115

Group type: EXPERIMENTAL
Intervention: Tight plaster cast during the first three weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients without algodystrophy
Number of subjects: 23
Study: 2695178

Group type: EXPERIMENTAL
Intervention: 10 Gy‐Co‐60 single dose of TBI plus 120 mg/kg of cyclophosphamide over 2 days (Group A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: 12 Gy Co‐60 of TBI in 6 fractions (2/day) plus 120 mg/kg of cyclophosphamide over 3 days (Group B)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 2

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 2
Study: 4441827

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg body weight)
Number of subjects: 80
Study: 30948595

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 92
Study: 28961595

Group type: EXPERIMENTAL
Intervention: Increased mastery over 28 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low mastery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High mastery
Number of subjects: 70
Study: 24856364

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Modified PE with imagery rescripting
Number of subjects: 65
Study: 23399113

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation with maintenance (RHBM group)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation without maintenance (RHB group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: RHBM group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: RHB group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 22174748

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study: 19855847

Group type: EXPERIMENTAL
Intervention: 15 microg of MSP3-LSP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30 microg of MSP3-LSP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Engerix B hepatitis B vaccine
Number of subjects: 45
Study: 17112442

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (9 g)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 11
Study: 15043655

Group type: EXPERIMENTAL
Intervention: Articles from Japan
Number of subjects: 20189

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 20189

Group type: EXPERIMENTAL
Intervention: Trend in Japan's contribution
Number of subjects: 20189
Study: 11567820

Group type: EXPERIMENTAL
Intervention: One isocenter radiosurgery (n = 44)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Two isocenter radiosurgery (n = 43)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both interventions (one and two isocenters)
Number of subjects: 87
Study: 9747366

Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7921908

Group type: EXPERIMENTAL
Intervention: 75 g of glucose in 300 ml of water (G trial)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 300 ml of sweetened water (P trial)
Number of subjects: 9
Study: 3202370

Group type: EXPERIMENTAL
Intervention: Active sustained-release theophylline preparation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo sustained-release theophylline preparation
Number of subjects: 16
Study: 31597020

Group type: EXPERIMENTAL
Intervention: Faster increment (30 ml/kg/day)
Number of subjects: 2804

Group type: COMPARATOR
Intervention: Slower increment (18 ml/kg/day)
Number of subjects: 2804
Study: 28929940

Group type: EXPERIMENTAL
Intervention: GGWB program (yoga-based prevention program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25728587

Group type: EXPERIMENTAL
Intervention: Combination therapy (infliximab and azathioprine)
Number of subjects: 188
Study: 24907494

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21962336

Group type: EXPERIMENTAL
Intervention: Interpersonal-psychotherapy-oriented childbirth education programme
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 194
Study: 19660005

Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg multiple doses (twice daily for 6 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban (various doses: 2.5, 5, 10, 20, 40 mg single dose; 5, 10, 20, 30 mg multiple doses)
Number of subjects: 0
Study: 17451422

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carvedilol vs Metoprolol tartrate
Number of subjects: 0
Study: 15021281

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 66
Study: 11549430

Group type: EXPERIMENTAL
Intervention: Early hormonal therapy with LHRH analogue plus radiotherapy (COMB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 90
Study: 9820373

Group type: EXPERIMENTAL
Intervention: Folate supplementation (5 mg/d for 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patients with ulcerative colitis (no folate supplementation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patients with Crohn's colitis (no folate supplementation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Folate status (measured in serum, whole blood, and colonic mucosa)
Number of subjects: 36